ASP 7266

Drug Profile

ASP 7266

Alternative Names: ASP7266

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 02 Mar 2018 Pharmacodynamics data from preclinical trials in Asthma presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2018)
  • 31 Jul 2017 Discontinued - Phase-I for Asthma in Japan (unspecified route) (Astellas pipeline, July 2017)
  • 26 Feb 2016 Phase-I clinical trials in severe Asthma in Japan (unspecified route) prior to January 2016 (Astellas Pharma pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top